This site is for US Healthcare Professionals only.
PIQRAY is the first and only therapy for aBC patients with a PIK3CA mutation

A CLEAR CHOICE AFTER PROGRESSION

The first therapy specifically for aBC
patients with a PIK3CA mutation

See Our ResultsTest For PIK3CA

The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

PIQRAY mPFS data

See the efficacy data

Learn more about the results of the pivotal SOLAR-1 trial.

 

 

See the data →

PIK3CA testing

Testing comes first

See the importance of testing for PIK3CA mutations.

 

 

Learn more →

PIQRAY Safety Profile

Review the safety profile

Explore the serious and most common adverse reactions and more safety information.

 

Review safety profile →

*Unless a recurrence or unmanageable toxicity occurs, per HR+/HER2- MBC American Society of Clinical Oncology® Guideline Update 2021.

Reference: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.5.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed January 19, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. 2. Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(35):3959-3977.